Drug Trial Radar · NCT07011719
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
720
Planned (sponsor's estimate)
Start
Sep 8, 2025
Primary completion
Apr 2028
Study completion Dec 2030
Sponsor
- Lead sponsor
- Arcus Biosciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib for patients who received anti-PD-1 or anti-PD-L1 therapy as part of the most recent regimen (either adjuvant monotherapy or first-line in combination with anti-CTLA-4 or VEGFR-TKI), with no more than 1 prior regimen in the metastatic setting.
Conditions
- Metastatic Clear Cell Renal Cell Carcinoma
- Advanced Clear Cell Renal Cell Carcinoma
Interventions
CasdatifanDrug
Administered as specified in the treatment arm
CabozantinibDrug
Administered as specified in the treatment arm
PlaceboDrug
Administered as specified in the treatment arm
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS) as assessed by Blinded Independent Central Review (BICR) according to RECIST 1.1Time frame: up to approximately 33 months
Locations
191 sites in 17 countries. Site status is shown where the registry gives one.
Research Site
Gilbert, Arizona · Recruiting
Research Site
Goodyear, Arizona · Recruiting
Research Site
Phoenix, Arizona · Recruiting
Research Site
Duarte, California · Recruiting
Research Site
Irvine, California · Recruiting
Research Site
La Jolla, California · Recruiting
Research Site
Los Angeles, California · Recruiting
Research Site
Palo Alto, California · Recruiting
Research Site
Sacramento, California · Recruiting
Research Site
San Diego, California · Recruiting
Research Site
Aurora, Colorado · Recruiting
Research Site
New Haven, Connecticut · Recruiting
Research Site
Washington D.C., District of Columbia · Recruiting
Research Site
Jacksonville, Florida · Recruiting
Research Site
Miami, Florida · Recruiting
Research Site
Orlando, Florida · Recruiting
Research Site
Atlanta, Georgia · Recruiting
Research Site
Atlanta, Georgia · Recruiting
Research Site
Newnan, Georgia · Recruiting
Research Site
Zion, Illinois · Recruiting
Research Site
Indianapolis, Indiana · Recruiting
Research Site
Louisville, Kentucky · Recruiting
Research Site
Jefferson, Louisiana · Recruiting
Research Site
Baltimore, Maryland · Recruiting
Research Site
Boston, Massachusetts · Recruiting
Research Site
Boston, Massachusetts · Recruiting
Research Site
Rochester, Minnesota · Recruiting
Research Site
St Louis, Missouri · Recruiting
Research Site
Omaha, Nebraska · Recruiting
Research Site
New Brunswick, New Jersey · Recruiting
Research Site
Buffalo, New York · Recruiting
Research Site
New York, New York · Recruiting
Research Site
Rochester, New York · Recruiting
Research Site
Chapel Hill, North Carolina · Recruiting
Research Site
Durham, North Carolina · Recruiting
Research Site
Cleveland, Ohio · Recruiting
Research Site
Portland, Oregon · Recruiting
Research Site
Monroeville, Pennsylvania · Recruiting
Research Site
Charleston, South Carolina · Recruiting
Research Site
Nashville, Tennessee · Recruiting
Showing 40 of 191 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.